Key Takeaways
- Record PAT in a lean quarter: PAT margin hit 42% (INR128 crores), the highest in company history, driven by the premiumization strategy, though management cautions this is a lean quarter and not a full-year run-rate.
- Premium products now 62% of B2C: Volume grew ~19% for premium products, with overall B2C volume up ~12%; the strategy of reducing tail-end, lower-margin products is working.
- Price cycle turning up: Prices have touched bottom and started rising, with international northward movements now visible in India, which should benefit B2B and IDB businesses.
- Capex cycle underway: INR125 crores planned over the next two years, with the Dahej plant starting this quarter and the Sotanala expansion targeting a 2026 start; the Sotanala plant alone could cross INR500 crores in its first full year at 65-70% utilization.
- What to watch next quarter: Whether the price uptick translates into B2B volume recovery, the pace of new product launches for the Kharif season, and any concrete plans for the Kaeros acquisition.
Premiumization Strategy & Product Portfolio
- Strategy mechanics: The company has been reducing tail-end lower-margin products and increasing 9(3) patented products; this shift is evidenced by a 3-4 year performance comparison and has taken premium products to 62% of the B2C business from 50-odd percent.
- Profitability threshold: Products become profitable from day one because they must qualify for a minimum 35% gross margin to enter the Maharatna or Focused Maharatna range; Focus Maharatna products generate INR10-15 crores gross margin, while Maharatna products generate INR1-1.5 crores.
- Product performance: Shinwa is the number one product in the portfolio; Izuki (next level of Pulsor from Nissan), Nissan SP, and Nissan Granule performed very well; Sofia, Hachiman, and Hercules are all part of the Focused Maharatna range.
- New launches: 10 new product launches in the first 9 months of this fiscal; at least more than half a dozen products coming next year, all expected to qualify in the Maharatna segment; 4 insecticides, 1 herbicide, and 1 fungicide are clearly visible, with possible additions in biologicals.
- Centran launch: Launched last month and sold 300 tons of granules in one month, signaling strong initial demand.
- Green Expert: A bundled rice herbicide launched 2.5 years back that is doing very well; the company aims to position it as a big brand and bring it into the Focused Maharatna range.
- New herbicide Altair: A new addition from the Nissan stable, available for the Kharif season in April-May.
- Exclusive product: A new product to be launched for the credit season will be exclusive for the first year, with partners potentially appointed later.
- Mixers development: The company is working on mixers for new products even before launch; in the long run, mixers will come and partners will be selected.
Rajesh Aggarwal: "The product becomes profitable from day 1. So there is no gestation period for a profitable product because if you are launching something in the Maharatna segment, focused Maharatna segment, you are very, very clear that it has to qualify the minimum gross margin of 35%."
Margin & Profitability
- Record PAT: Generated total PAT of INR128 crores, the highest in company history; even in a full year, the company has not generated this type of PAT margin in the past.
- Premiumization driver: The premiumization strategy is directly responsible for increasing profitability to 42% PAT margin, though management stresses this is a lean quarter and should not be taken as a full-year number.
- Gross margin target: Targeting gross margin of 30% to 35% in the next 1-2 years.
- EBITDA target: EBITDA target of about 12% to 13%; already maintaining 11.7% EBITDA margin over 9 months, with closing expected to be good with double-digit margins.
- No loss-making drag: The company does not do business for making losses; rare cases of losses happened 3 years back when the market slashed 50%, but currently nothing is a negative contributor.
- Marketing investment: Marketing expenses increased this year, with the crop adviser budget increased and more money being spent in the market; the company is continuously investing in B2C across market, facilities, and systems to strengthen the team.
Rajesh Aggarwal: "The premiumization strategy has played out very well. The effort to make it is in full swing, and we are continuously working around these new products, which is responsible for increasing the profitability of this quarter and taking it to 42%, though this is a lean quarter and we cannot take it as a full year number."
Price Environment & Raw Material
- Cycle turning: Prices have touched bottom and started going up; northward movements in the international market are now visible in the Indian market, which will have a good impact on B2B and IDB businesses.
- Procurement underway: The company has started planning for the next Kharif season, begun procuring raw material, and plants have started manufacturing; there are signals of shortages in the market.
- B2B impact: The industry was impacted in Q3, which hit B2B sales particularly; the price uptick should help reverse this.
Rajesh Aggarwal: "The prices have touched the bottom already and they have started going up. As the prices goes up, the market prices are also going to go up because it is going to increase for everyone."
Capacity Expansion & Capex
- Dahej plant: Going to start very soon in this quarter.
- Sotanala expansion: Two parts: formulation and technical; the first building will start at 70%-80% production immediately as it is a DCS plant with products the company already has expertise in; some bulks will be transferred from other plants, while new technologies will go through another plant first before being established at Sotanala.
- Sotanala potential: If the plant achieves even 65-70% utilization, it will cross INR500 crores in the first full year itself.
- Capex envelope: INR125 crores over the next 2 years, with the majority going into the next fiscal and some spillover possible.
- IIL Biologicals plant: Setting up a new plant for IIL Biologicals at the Shamli site, where IIL already has one biological plant; the company has a big piece of land purchased across various subsidiaries.
Rajesh Aggarwal: "So in terms of number, I can say that if it achieves even 65%, 70%, it will be crossing INR500 crores in the first year itself, first full year."
Biologicals & New Initiatives
- Seaweed product: Launched 2-3 months back in partnership with a startup; the product is a mixture of 2 seaweeds with an innovative booster and has shown superior results versus international and domestic brands.
- Seaweed targets: Should cross at least 1 lakh liters in sales in the next full year (FY26); long-term potential of INR50-70 crores in 4-5 years, with the aim to make it the brand leader in the segment.
- Biologicals vision: Biologicals will contribute in a big way in the future, both in domestic and international markets; the medium term should show big growth.
- Biologicals R&D: The company is applying for a lot of patents and working on R&D of biological products in many new ways; management describes it as a very futuristic business and declined to share details, calling them secret.
- CRM program: Launched an own program to tap farmers, using HSBC system as CRM; connecting crop advisers through an app with a training module.
Rajesh Aggarwal: "It is a very futuristic business actually. So we are applying for a lot of patents, and we are working on R&D of biological products in many new ways. So these are secret things. I cannot declare too much."
Organization & Acquisitions
- New CMO: Mr. Dushyant Sood joined as CMO for the first time; he has vast experience of more than 30 years in marketing and sales in large companies.
- CXO build-out: The company is working on building the organization; CXO positions to be filled, with new faces at VP/senior level for the next Kharif season; strengthening across marketing, sales, R&D, manufacturing, and operations.
- Kaeros acquisition: Acquired for ~INR6 crores; the company has paid-up capital of ~INR4.8 crores; land was purchased to build a plant; currently used for green land trial purposes and holds about one dozen import licenses.
- Kaeros rationale: Kaeros gives the opportunity to import technicals that the company generally purchases from competition at a little higher price, so it will improve profitability.
- Distributor network: About 4%-5% increase in distributors, with a higher increase in retailers expected.
Rajesh Aggarwal: "Kaeros gives the opportunity to import these technicals, which we generally purchase from our competition at a little higher price. So it will improve the profitability of the company."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Premium product mix | Grow to 65% of B2C from current 62% | Next 1-2 years |
| Premium product volume growth | Minimum 20% YoY volume growth in B2C premium products every year | Continuous target for next 4-5 years |
| Gross margin | Reach 30% to 35% | Next 1-2 years |
| EBITDA margin | Achieve about 12% to 13% | Implied medium-term |
| Working capital | Improve cycle by at least 20-25 days | Next year |
| New product launches | At least more than half a dozen products, all qualifying in Maharatna segment | Next fiscal year |
| Seaweed product sales | Cross at least 1 lakh liters | FY26 |
| Seaweed long-term revenue | Generate INR50-70 crores, become brand leader | 4-5 years |
| Sotanala plant start | Plant to begin operations | 2026 |
| Sotanala first full year revenue | Cross INR500 crores at 65-70% utilization | First full year after start |
| Capex | INR125 crores, majority in next fiscal | Next 2 years |
| Kaeros plans | Ready with plans | By next investor call |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue from operations | ₹358 cr, YoY growth ~18% |
| 9M FY25 revenue from operations | ₹1,641 cr |
| EBITDA | ₹61 cr, up from ₹24 cr in Q3 FY24 |
| EBITDA margin | 8.6% |
| 9M FY25 EBITDA | ₹193 cr, margin 11.7% |
| PAT | ₹17.4 cr, YoY growth ~42% |
| 9M FY25 PAT | ₹128 cr, YoY growth ~36%, highest in company history |
| B2C sales contribution | 82% of total sales |
| B2B sales contribution | 11% of total sales |
| Exports contribution | 7% of total sales |
| Premium products share of B2C sales | 55% in Q3, 62% in 9M FY25 |
| Product mix: Insecticides | 49% of total sales |
| Product mix: Herbicides | 37% of total sales |
| Product mix: Fungicides | 9% of total sales |
| B2C volume growth | ~7-8% YoY |
| Premium products volume growth (9M) | ~19% YoY |
| Premium products value growth (9M) | ~12% YoY |
| Capex planned | ₹125 cr over next 2 years, majority in next fiscal |
| Sotanala plant revenue potential at 65-70% capacity | Crossing ₹500 cr in first full year |
| New product launches in current fiscal | 10 |
| New launches planned for next fiscal | At least 6, plus possible biological additions |
| Focus Maharatna products currently | 11, targeting 15 |
| Export revenue guidance for FY25 | Crossing ₹100 cr, below earlier target of ₹150 cr |
| Kaeros acquisition cost | ₹6.3 cr, including land and business value |
| Seaweed biological product FY26 sales target | At least 1 lakh liters, ~₹10 cr |
| Distributor network increase expected | ~4-5% |